2025 Annual Report

2025 Annual Report

✨ AI Summary

The 2025 Annual Report details Sunflower Pharmaceutical Group Co., Ltd.'s financial performance. The company reported a significant decrease in operating revenue to ¥2,317,958,832.50 and a net loss of ¥309,535,978.07. Key figures show a -31.36% year-on-year change in operating revenue and a -189.79% change in net profit. The report highlights operational losses as the main factor affecting profit and outlines plans for product enhancement and market expansion despite current challenges.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

First Section Important Reminder, Directory and Explanation

The company's board of directors and senior management ensure the truthfulness, accuracy, and completeness of the annual report content, avoiding false records and misleading statements, and bearing legal responsibilities.

The person responsible for the company is [blank], the main accountant is [blank], and the person in charge of the financial report is [blank].

Except for the listed directors, other matters are handled by the next board meeting.

Name	Position	Birth Year	Reason for Appointment
[blank]	Independent Director	[blank]	[blank]
[blank]	Independent Director	[blank]	[blank]
[blank]	Independent Director	[blank]	[blank]

The company’s report includes the development prospects and planning of the company, as well as the risks faced by investors.

The company may face risks related to raw material price fluctuations, new product introductions, and management risks. The above risks are detailed in the third management discussion and analysis section, "Company's Future Development Prospects."

The company’s next board meeting will review the profit distribution proposal: as of December 31, 2025, the company's total share capital is 584,000,000 shares, with a proposed cash dividend of ¥2 per share (including tax), distributing 0 shares (including tax), without increasing the registered capital.